<DOC>
	<DOCNO>NCT02509104</DOCNO>
	<brief_summary>The primary objective study determine bioavailability FDC capsule formulation dutasteride tamsulosin hydrochloride ( 0.5 milligram [ mg ] /0.2 mg ) relative coadministration one dutasteride 0.5 mg capsule one tamsulosin HCl 0.2 mg tablet healthy male subject feed fasted state . This open-label , randomize , single dose , two-way crossover study enrol healthy male subject , split fast ( Cohort 1 ) fed ( Cohort 2 ) condition . In cohort , one FDC capsule formulation dutasteride 0.5 mg/tamsulosin HCl 0.2 mg administer one treatment period coadministration dutasteride tamsulosin hydrochloride different treatment period . Each subject enrol allow participate one cohort ( i.e , receive treatment fast fed condition ) participate treatment period . The two treatment period separate minimum washout period 28 day . The total duration study subject approximately 2.5 month screen final follow-up visit .</brief_summary>
	<brief_title>Bioavailability Study Fixed Dose Combination ( FDC ) Dutasteride Tamsulosin Hydrochloride ( HCl ) Relative One Dutasteride One Tamsulosin HCl Tablet Healthy Male Subjects</brief_title>
	<detailed_description />
	<mesh_term>Hyperplasia</mesh_term>
	<mesh_term>Prostatic Hyperplasia</mesh_term>
	<mesh_term>Tamsulosin</mesh_term>
	<mesh_term>Dutasteride</mesh_term>
	<criteria>Male subject age 18 65 year age inclusive , time signing informed consent . Healthy determine investigator medically qualify designee base medical evaluation include medical history , physical examination , laboratory test cardiac monitoring . A subject clinical abnormality laboratory parameter ( ) is/are specifically list inclusion exclusion criterion , outside reference range population study may include investigator consultation Medical Monitor require agree document find unlikely introduce additional risk factor interfere study procedure . Body weight &gt; = 50 kilogram ( kg ) body mass index ( BMI ) within range 18 30 kg per meter square ( m^2 ) ( inclusive ) . Capable give sign informed consent include compliance requirement restriction list consent form protocol . Alanine aminotransferase ( ALT ) bilirubin &gt; 1.5xUpper limit normal ( ULN ) ( isolated bilirubin &gt; 1.5xULN acceptable bilirubin fractionate direct bilirubin &lt; 35 percent ) . Current chronic history liver disease , know hepatic biliary abnormality ( exception Gilbert 's syndrome asymptomatic gallstone ) . History postural hypotension , dizziness , poor hydration , vertigo , vasovagal reaction sign symptom orthostasis , opinion investigator could exacerbate tamsulosin result put subject risk injury . History diabetes peptic ulcer disease uncontrolled medical management . Current history : Breast cancer clinical breast examination find suggestive breast malignancy ; Malignancy within past five year , except basal cell carcinoma skin . Subjects prior malignancy evidence disease least past 5 year eligible . Prior medical history evidence prostate cancer ( e.g. , positive biopsy , suspicious ultrasound , suspicious digital rectal examination [ DRE ] ) . Patients suspicious ultrasound DRE negative biopsy within precede 6 month stable prostate specific antigen ( PSA ) eligible study . Based average correct QT ( QTc ) value triplicate ECGs obtain brief recording period : QTcF &gt; 450 millisecond ( msec ) . Subjects must abstain take prescription nonprescription drug ( include vitamin dietary herbal supplement ) , within 7 day ( 14 day drug potential enzyme inducer ) 5 halflives ( whichever longer ) prior first dose study medication completion followup visit , unless opinion Investigator sponsor medication interfere Study . History regular alcohol consumption within 6 month study define : For United States site : average weekly intake &gt; 14 drink male &gt; 7 drink female . One drink equivalent 12 gram ( g ) alcohol : 12 ounce ( 360 millilitre [ mL ] ) beer , 5 ounce ( 150 mL ) wine 1.5 ounce ( 45 mL ) 80 proof distil spirit . History sensitivity study medication , component thereof history drug allergy , opinion investigator Medical Monitor , contraindicate participation . Presence hepatitis B surface antigen ( HBsAg ) , positive hepatitis C antibody test result screen within 3 month prior first dose study treatment . A positive prestudy drug/alcohol screen . A positive test human immunodeficiency virus ( HIV ) antibody . Where participation study would result donation blood blood product excess 500 mL duration study . The subject participate clinical trial receive investigational product within following time period prior first dose day current study : 50 day , 5 halflives twice duration biological effect investigational product ( whichever longer ) . Exposure four new chemical entity within 12 month prior first dose day . Unable swallow retain oral medication .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>Bioavailability</keyword>
	<keyword>Dutasteride</keyword>
	<keyword>Healthy Male Subjects</keyword>
	<keyword>Fixed Dose Combination</keyword>
</DOC>